InVivoScribe (IVS) Technologies is a privately-held biotechnology company located in San Diego, California, with a sales and distribution office (IVS Technologies, SARL) located in La Ciotat, Provence, France.
The company is dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, cutting-edge products and technologies for molecular diagnostics, hematopathology and cDNA synthesis.
The company was founded in 1995 based upon InVivoScribe's patented in vivo cDNA synthesis technologies that convert unstable cellular messenger RNA into stable complementary DNA within the living cells and tissues. Our products enhance the quality and reproducibility of cDNA products and eliminate difficulties and bias associated with RNA extraction and in vitro methods for cDNA synthesis.
IVS provides a comprehensive selection of PCR-based gene rearrangement, gene translocation, and gene mutation testing reagents and controls. Customers include many of the world's leading pharmaceutical and biotechnology companies, medical centers, cancer research centers, reference laboratories and molecular testing centers.
Our products are used to identify, classify, and monitor leukemias, lymphomas and other lymphoproliferative disease.
InVivoScribe provides tests and services to assist in the development of pharmaceutical agents and devices. We also produce OEM reagents for specific analytical platforms.
InVivoScribe's gene rearrangement products, and certain of our gene mutation testing products are covered by exclusive-licensed patents. The company is debt-free and has been profitable since the beginning of this decade.
By using this website, you agree to the Terms of Use.
